According to the Complaint, Mylan N.V. is a Dutch company with its global headquarters located in Pennsylvania, United States. Mylan began in 1961 as a privately owned distributor for pharmacies and doctors. In 1965, Mylan relocated to Pennsylvania and in 1973, Mylan became publicly traded. In 2015, Mylan acquired Abbott Laboratories’ non-U.S. market specialties and branded generics business and became a public limited liability company in the Netherlands.

The Complaint alleges that during the Class Period, Mylan made false and/or misleading statements and/or failed to disclose that: (1) Mylan's Morgantown facility was in significant violation of the FDA's Current Good Manufacturing Practice regulations; (2) Mylan would need to engage in a massive restructuring and remediation program; (3) Mylan's North American Segment would be substantially impacted by said program, which would in turn materially impact Mylan's financial health; (3) Mylan lacked effective internal control over financial reporting; and (4) as a result of the foregoing, the Company's financial statements were materially false and misleading at all relevant times.

This case was voluntarily dismissed on December 30, 2019.